Arbutus Biopharma Corp splits its revenue into 3 lines in its filings. The largest line in Q2 of fiscal 2026, the quarter ended Jun 30, 2026 was License at $632,000, 62% of the total.
USD in millions. The percent under a figure is the change from the same quarter a year earlier.
| Line |
TTM
Jun 30, 2026
|
Q2 FY2026
Jun 30, 2026
|
Q1 FY2026
Mar 31, 2026
|
Q4 FY2025
Dec 31, 2025
|
Q3 FY2025
Sep 30, 2025
|
Q2 FY2025
Jun 30, 2025
|
Q1 FY2025
Mar 31, 2025
|
Q4 FY2024
Dec 31, 2024
|
Q3 FY2024
Sep 30, 2024
|
|---|---|---|---|---|---|---|---|---|---|
| Revenue |
182
|
1
|
179
|
1
|
1
|
11
|
2
|
2
|
1
|
| License |
—
|
1
share 62.3%
|
179
share 99.8%
|
—
|
—
|
—
|
—
|
—
|
—
|
| Collaboration And Contracts |
—
|
0
-98.0%
share 19.9%
|
0
-84.5%
share 0.1%
|
1
-25.1%
share 75.4%
|
0
-63.5%
share 52.9%
|
10
share 95.1%
|
1
share 74.6%
|
1
share 67.2%
|
1
share 57.3%
|
| Non Cash Royalty |
—
|
0
-65.8%
share 17.8%
|
0
-59.6%
share 0.1%
|
0
-49.8%
share 24.6%
|
0
-56.5%
share 47.1%
|
1
share 4.9%
|
0
share 25.4%
|
1
share 32.8%
|
1
share 42.7%
|
How these figures are calculated
Quarterly columns are single-quarter amounts. When a 10-Q reports only a year-to-date total, as cash flow statements do, the quarter is that total minus the previous quarter's year-to-date total. The fourth quarter is the annual report's full year minus the first nine months. A column marked YTD is a year-to-date total, shown when the earlier report needed for the single quarter is missing. USD in millions. Each group is a separate split of total revenue, so the groups are not added together. Share of revenue is that line divided by total revenue. The first column adds the latest year-to-date segment amount to the last fiscal year and subtracts the year-ago year-to-date amount. More on our methodology.
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- ABUS (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- British Columbia, Canada
- Headquarters
- Warminster, PA
- SEC filer status
- Non-accelerated filer, Smaller reporting company
- SEC CIK
- 1447028
- Former names
- TEKMIRA PHARMACEUTICALS CORP (until Aug 3, 2015); TEKMIRA PHARMACEUTICALS Corp (until Aug 3, 2015)
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Source: SEC EDGAR filings. This is company-reported data, not investment advice.